WNT Signaling in Neuroblastoma

Becker, Juergen C.; Wilting, Jörg

doi:10.3390/cancers11071013

Cited by 31 publications

(25 citation statements)

References 106 publications

(142 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review provides an overview of the current state‐of‐the‐art molecular understanding of the development and progression of NB, with a particular emphasis on genetic aberrations and disrupted molecular pathways. As noted, several excellent reviews have been published, covering recent advances made in pathogenesis, diagnosis, and clinical management of NB and interested readers are referred to those excellent publications 4,9,22,29,42,46–72 . In this review, we will emphasize how these advances in knowledge about molecular pathogenesis can be translated to developing molecular targeted therapies for NB management, especially personalized therapies.…”

Section: Introductionmentioning

confidence: 99%

Molecular targeting therapies for neuroblastoma: Progress and challenges

Zafar

Wang

Liu

et al. 2020

Medicinal Research Reviews

220

139

View full text Add to dashboard Cite

There is an urgent need to identify novel therapies for childhood cancers. Neuroblastoma is the most common pediatric solid tumor, and accounts for ~15% of childhood cancer‐related mortality. Neuroblastomas exhibit genetic, morphological and clinical heterogeneity, which limits the efficacy of existing treatment modalities. Gaining detailed knowledge of the molecular signatures and genetic variations involved in the pathogenesis of neuroblastoma is necessary to develop safer and more effective treatments for this devastating disease. Recent studies with advanced high‐throughput “omics” techniques have revealed numerous genetic/genomic alterations and dysfunctional pathways that drive the onset, growth, progression, and resistance of neuroblastoma to therapy. A variety of molecular signatures are being evaluated to better understand the disease, with many of them being used as targets to develop new treatments for neuroblastoma patients. In this review, we have summarized the contemporary understanding of the molecular pathways and genetic aberrations, such as those in MYCN, BIRC5, PHOX2B, and LIN28B, involved in the pathogenesis of neuroblastoma, and provide a comprehensive overview of the molecular targeted therapies under preclinical and clinical investigations, particularly those targeting ALK signaling, MDM2, PI3K/Akt/mTOR and RAS‐MAPK pathways, as well as epigenetic regulators. We also give insights on the use of combination therapies involving novel agents that target various pathways. Further, we discuss the future directions that would help identify novel targets and therapeutics and improve the currently available therapies, enhancing the treatment outcomes and survival of patients with neuroblastoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular targeting therapies for neuroblastoma: Progress and challenges

Zafar

Wang

Liu

et al. 2020

Medicinal Research Reviews

220

139

View full text Add to dashboard Cite

show abstract

“…support an important role for neuroblastomas. In the SH-SY5Y neuroblastoma cell line, RNAi suppression of WNT1 expression has been shown to significantly reduce cell viability (27) .…”

Section: Wingless / Int (Wnt) Signal Pathwaymentioning

confidence: 99%

Neuroblastoma and Hippo Signaling Pathway

Özşengezer¹,

Altun²,

Olgun³

2021

BUCH

View full text Add to dashboard Cite

Neuroblastoma (NB) is a malignant tumor often seen in early childhood and originating from the sympathetic nervous system.Hippo signal pathway is a mechanism involved in organ growth, differentiation and plays an important role in stem cells, cancer stem cells and tumorigenesis.YAP,which is the transcription co-activator, is an important part of this mechanism and the inhibition effect of YAP inhibition on cell proliferation highlights the effect of this pathway on cancer. In the diagnosis and prognosis of pediatric tumors, more beneficial clinical applications of YAP and other routes can be considered and further research can be expected.Hippo pathway members, especially YAP, are potential new treatment targets for tumors that show overexpression. Along with the clinical features that affect the progression of the NB, chromosomal abnormalities and both oncogenes and tumor suppressor genes need to be evaluated together to develop new treatment strategies, especially in aggressive NB’s. In recent studies, YAP inhibition has been shown to impair tumor growth and NB’s cisplatin resistance.This defines YAP as a potential therapeutic target, especially for cisplatin-resistant NB.Hippo is a new glimmer of hope for NB in the signal pathway and open to study and development since all steps cannot be actively determined.

show abstract

“…Aberrant Wnt signaling caused by mutation/epigenetic changes has been reported in many type of cancers such as colon rectal cancer, breast cancer, hepatocellular carcinoma, leukemia etc. [247][248][249][250][251]. Regulation of Wnt signaling has been associated with cancer stem cells, tumor microenvironment and anti-cancer immune response [252,253].…”

Section: Growth Factor Signalingmentioning

confidence: 99%

Phytochemicals targeting metabolic reprogramming in cancer: an assessment of role, mechanisms, pathways and therapeutic relevance

Khan¹,

Siddiqui²,

Husain³

et al. 2020

Preprint

View full text Add to dashboard Cite

The metabolism of cancer is remarkably different from that of normal cells and confers variety of benefits including the promotion of other cancer hallmarks. As the rewired metabolism is a near-universal property of cancer cells, efforts are underway to exploit metabolic vulnerabilities for therapeutic benefit. In the continued search for a safer and effective ways of cancer treatment, structurally diverse plant-based compounds have gained substantial attention. Here, we present an extensive assessment of the role of phytocompounds in modulating cancer metabolism and make a case for the use of plant-based compounds in targeting metabolic vulnerabilities of cancer. We discuss the interactions of phytocompounds with major metabolic pathways and evaluate the role of phytochemicals in the regulation of growth signaling and transcriptional programs involved in metabolic transformation of cancer. Lastly, we examine the potential of these compounds in clinical management of cancer along with limitations and challenges

show abstract

WNT Signaling in Neuroblastoma

Cited by 31 publications

References 106 publications

Molecular targeting therapies for neuroblastoma: Progress and challenges

Molecular targeting therapies for neuroblastoma: Progress and challenges

Neuroblastoma and Hippo Signaling Pathway

Phytochemicals targeting metabolic reprogramming in cancer: an assessment of role, mechanisms, pathways and therapeutic relevance

Contact Info

Product

Resources

About